Is Enzyme Finance a Good Investment?
| TVL | $82M |
| FDV | $12M |
| TVL/FDV | 6.84x |
| Risk Grade | B- |
| Value Grade | D+ |
Value Accrual: Does the Enzyme Finance Token Capture Value?
Enzyme Finance scores D+ on Hindenrank's value accrual framework (30/100), indicating below-average value accrual with significant gaps in fee capture or sustainability. Fee capture scores 8/25 — limited, with most protocol revenue not yet accruing to the token. Token distribution is rated 10/25 (somewhat concentrated, raising concerns about governance capture), and emission sustainability sits at 8/25. The competitive moat dimension scores 4/25.
Protocol Health: Is Enzyme Finance Still Growing?
Enzyme Finance's vitality risk score is 6/10 on Hindenrank's rubric (lower is healthier). This suggests moderate health — Enzyme Finance is maintaining activity but may be showing signs of plateauing growth or reduced developer engagement. The protocol is functional but may not be accelerating.
Risk-Adjusted View: Is the Upside Worth the Risk?
Risk-Adjusted Position
Dead MoneyEnzyme Finance sits in the Dead Money quadrant — low risk (B-) but poor value accrual (D+). While the protocol itself is relatively safe, the token does not effectively capture the value it creates. Investors may want to wait for governance changes or fee-switch activation before allocating.
Risk Context
Enzyme Finance carries a risk grade of B- (28/100), classified as moderate risk — some novel mechanisms, generally well-understood. While no critical-severity interactions were identified, 1 high-severity interaction warrant attention. The primary risk factor is: Vault managers have discretion over asset allocation within policy constraints. A vault manager could make poor investment decisions or exploit their position within the bounds of their vault's policies, resulting in losses for depositors who rely on the manager's competence.
Read our full safety analysis →Should you buy Enzyme Finance?
Enzyme Finance scores D+ on Hindenrank's value accrual framework, placing it among the below-average DeFi protocols. Fee capture scores 8/25 — limited, with most protocol revenue not yet accruing to the token. Token distribution is somewhat concentrated, raising concerns about governance capture, and emission sustainability sits at 8/25. On the risk side, Enzyme Finance carries a B- grade (28/100), which is moderate risk — some novel mechanisms, generally well-understood. The combined risk-value position places Enzyme Finance in the Dead Money quadrant.
Enzyme Finance investment outlook for 2026
With $82M in total value locked and FDV of $12M, giving a TVL/FDV ratio of 6.84, Enzyme Finance's fundamentals do not strongly support the current valuation from a usage perspective. The competitive moat dimension scores 4/25, suggesting limited moat, leaving the protocol vulnerable to competitive pressure.Investors should weigh these fundamentals alongside market conditions and their own risk tolerance.
This analysis is based on cryptoeconomic fundamentals, not price prediction. It is not financial advice. Full methodology
Weekly Commentary
ProWeek of March 3, 2026
Enzyme's B- risk grade says the protocol won't blow up, but the D+ value score says holding the token won't reward you for caring. At $87M TVL with weak fee capture and no compelling token accrual, this is a well-built product that functions more as infrastructure for others than as an investment — textbook dead money. The risk engineering is solid; the tokenomics are not.
Exploring options?
Compare DeFi Alternatives →